- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03957798
Evaluation of a Motion-Activated Refusal-Skills Training Video Game for Prevention of Substance Use Disorder Relapse
May 17, 2019 updated by: George Washington University
The project proposes to continue the development of an intervention for relapse prevention in the form of a professional quality video game which rewards drug-rejecting physical motions and spoken refusal phrases.
Phase I research findings showed that youth in recovery experienced increased low craving levels, strong levels of satisfaction, and interest in attending treatment sessions where the intervention is available - an important outcome since failure to attend treatment is highly correlated with relapse.
In Phase II, the investigators propose to modify and expand the prototype based on customer feedback from treatment centers, counselors and patients.
The investigators will test the effectiveness of the motion and voice-controlled game in a randomized controlled trial of youths in treatment for opioid use disorder who have access to the game for a month.
The investigators will measure the effect of gameplay on successful completion of detoxification/inpatient treatment and rates of linkage to next level of outpatient treatment.
The investigators will also measure the effect of gameplay compared to treatment as usual (TAU) during a subsequent episode of outpatient treatment (following inpatient), on rates of treatment attendance, treatment retention, urine drug test results, substance use self-report, treatment alliance, drug craving, and treatment satisfaction.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 25 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- attending the MMTC inpatient program for primarily opioid or marijuana use disorder treatment
- ability to speak English
Exclusion Criteria:
- presence of a comorbid psychiatric condition that would make participation unsafe (eg, acute suicidality or unstable psychosis)
- pregnancy (because of the physical exertion required to play the game)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control (Treatment as Usual)
TAU consists of inpatient substance abuse treatment, followed by referral to outpatient treatment.
For those who live within the outpatient geographic catchment area of the treatment center, patients are subsequently admitted to outpatient levels of care at treatment center.
For the non-opioid population (primarily marijuana), this consists of the intensive outpatient program counseling sessions starting at a frequency of 3x/wk, tapering to 1x/wk with clinical progress with 12 wks target length of service.
For the opioid population, this consists of a specialty youth opioid program with group and individual counseling, relapse prevention medications treatment, psychiatric assessment and treatment, also starting at a frequency of 3x/wk, tapering to 1x/wk with clinical progress, with indefinite target length of service.
For those not within the outpatient geographic catchment area, patients are referred to local continuing care and outpatient levels of care convenient to their homes.
|
|
Experimental: Intervention (Treatment as usual + game)
|
RecoveryWarrior 2.0 was developed for use with Microsoft Kinect running on a Windows personal computer.
All games made use of whole-body motion detection and the same voice-recognition feature.
Body motions included a variety of arm, leg, and whole-body movements to physically enact the motions of destroying or evading images of drugs and drug paraphernalia.
Voice features consisted of recognition of the refusal phrase "I'm Clean" Players could say or shout "I'm Clean" in order to gain additional strength for their game play avatar.
All game art was created in a hyperrealistic, idealized, heroic style.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in craving
Time Frame: baseline, discharge (up to 2 weeks from baseline), 4 week, 8 week
|
For cravings, the 5-item Penn Alcohol Craving Scale was included at baseline, discharge, and postdischarge follow-up surveys, but modified to apply to marijuana and opioid use.
It assessed the intensity of a participant's cravings (0=none at all to 6=very strong; sum of a maximum total of 30 points).
|
baseline, discharge (up to 2 weeks from baseline), 4 week, 8 week
|
Change in self-efficacy
Time Frame: baseline, discharge (up to 2 weeks from baseline), 4 week, 8 week
|
Self-efficacy for refusal of drugs was measured using the Marijuana Resistance Self-Efficacy scale at baseline, discharge, and follow-up surveys.
It used a 4-item, 4-point scale (1=very easy to 4=very hard) that asked participants how easy or hard it would be to refuse the drug if offered and explain why they did not want it, why they wanted to avoid the situation in the first place, and why they wanted to leave the situation.
It was adapted so that there was a similar version for opioid use.
Participants were only asked about the primary drug for which they enrolled in treatment (ie, marijuana or opioids).
|
baseline, discharge (up to 2 weeks from baseline), 4 week, 8 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Refusal Skill
Time Frame: 4 week
|
Refusal skills were measured by asking participants if they agreed that they would use the phrase "I'm Clean" to refuse drugs (1=not agree to 5=highly agree), if they had used the phrase "I'm Clean" since discharge to refuse drugs, and if the phrase "I'm Clean" still rings in their head (not at all, less than once per week, a few times a week, or more often).
|
4 week
|
Abstinence of drug use
Time Frame: Baseline, 4 week, 8 week
|
Participants were asked about the primary drug that they were in treatment for.
Opioid and marijuana use at follow-up was ascertained by self-report of any use in the past 7 and 30 days.
|
Baseline, 4 week, 8 week
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Counselor Alliance
Time Frame: discharge (up to 2 weeks from baseline), 4 week, 8 week
|
Treatment rating was measured in three ways.
First, it was measured with the Counselor Alliance Scale, which was taken from the Working Alliance Inventory, and used to measure treatment progress with the counselor at discharge, 4 weeks, and 8 weeks.
The Counselor Alliance Scale uses 7-items and 7-points to measure how well participants believe counselors are working with them to improve their situation (1=never to 7=always).
|
discharge (up to 2 weeks from baseline), 4 week, 8 week
|
Treatment Rating
Time Frame: 4 week, 8 week
|
The treatment rating was also measured by asking participants about their satisfaction with inpatient care at the time of discharge and satisfaction with outpatient care at the 4-week and 8-week follow-up surveys.
|
4 week, 8 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Daniel Greenberg, BFA, Media Rez LLC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 5, 2016
Primary Completion (Actual)
June 21, 2016
Study Completion (Actual)
October 31, 2016
Study Registration Dates
First Submitted
April 16, 2019
First Submitted That Met QC Criteria
May 17, 2019
First Posted (Actual)
May 21, 2019
Study Record Updates
Last Update Posted (Actual)
May 21, 2019
Last Update Submitted That Met QC Criteria
May 17, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MREZ-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid Use
-
Sharon WalshNational Institute on Drug Abuse (NIDA)Completed
-
Aurora Health CareUniversity of Chicago; University of California, Santa Cruz; Rogers Behavioral...RecruitingSubstance Use | Methamphetamine-dependence | Opioid Use | Opioid-use Disorder | Cocaine Use Disorder | Cocaine Use | Methamphetamine AbuseUnited States
-
Indonesia UniversityRecruiting
-
Lawson Health Research InstituteNot yet recruiting
-
University of Colorado, DenverUniversity of Nebraska; Agency for Healthcare Research and Quality (AHRQ)Completed
-
Zulekha HospitalsCompleted
-
Peking University People's HospitalCompleted
-
University of UtahCompleted
-
University Health Network, TorontoOntario Ministry of Health and Long Term CareCompleted
Clinical Trials on RecoveryWarrior 2.0
-
BrainQ Technologies Ltd.Completed
-
Work Life HelpNational Institute on Aging (NIA)Active, not recruitingPsychosocial Deprivation | Work-Related Stress | Life-work ImbalanceUnited States
-
Aarhus University HospitalNot yet recruitingPatella DysplasiaDenmark
-
NYU Langone HealthNational Institutes of Health (NIH); Alzheimer's Association; LiteCure LLCRecruitingAlzheimer Disease | Mild Cognitive ImpairmentUnited States
-
Imperial College LondonNational Institute for Health Research, United KingdomCompletedMental Health Disorder | Child Behavior Problem | Self Injurious Behavior | Adolescent Behavior ProblemUnited Kingdom
-
Otivio ASEnrolling by invitationPain | Multiple Sclerosis | Spasticity, MuscleNorway
-
University GhentCompletedChronic DiseaseBelgium
-
University of PittsburghThe Grable Foundation; Department Human Services, Pennsylvania; Fisa FoundationCompletedViolence, Domestic | Coping Skills | Violence in Adolescence | Adolescent Behavior | Violence, Sexual | Violence, Physical | Violence, Non-accidental | Group, Peer | Emotional Abuse | Communication, PersonalUnited States
-
Hospital Clinic of BarcelonaInstitut d'Investigacions Biomèdiques August Pi i Sunyer; Centro de Investigación... and other collaboratorsSuspended
-
University of California, San DiegoNational Institutes of Health (NIH); Small Steps Labs, LLCCompletedOverweight and ObesityUnited States